Screener
Replimune Group REPL Business Segments — RP1 program costs by study
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Replimune Group in its filing.
Tagged under the XBRL concept repl:ResearchAndDevelopmentProgramExpense.
The source filing: Replimune Group’s 10-Q, filed February 3, 2026.
- Filed
- Feb 3, 2026, 8:12 AM EST
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q4 2025
- Accession
- 0001628280-26-004805
| Operating expenses: | Three Months Ended December 31, 2025 / (Amounts in thousands) | Three Months Ended December 31, 2024 / (Amounts in thousands) | Nine Months Ended December 31, 2025 / (Amounts in thousands) | Nine Months Ended December 31, 2024 / (Amounts in thousands) |
|---|---|---|---|---|
| CERPASS | 1,012 | 1,611 | 3,653 | 5,573 |
| IGNYTE-3 | 4,219 | 2,375 | 15,554 | 4,909 |
| Other RP1 study costs | 5,200 | 1,590 | 15,162 | 7,075 |
| RP2 | 7,729 | 4,409 | 16,857 | 8,322 |
| RP3 | 826 | 1,434 | 2,262 | 3,856 |
| Unallocated research and development expenses¹: | 30,432 | 31,572 | 102,401 | 89,695 |
| Selling, general and administrative | 18,728 | 18,015 | 77,721 | 46,827 |
| Total operating expenses | 71,868 | 66,019 | 246,581 | 182,299 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Replimune Group's business segments — RP1 program costs by study?
- Replimune Group (REPL) reported business segments — RP1 program costs by study of $7.73M in Q4 2025.
- How has Replimune Group's business segments — RP1 program costs by study changed year-over-year?
- Replimune Group's business segments — RP1 program costs by study increased by 75.3% year-over-year, from $4.41M to $7.73M.
- What does business segments — RP1 program costs by study mean?
- Represents the direct research and development expenditures specifically allocated to the clinical development of the RP1 product candidate. This metric tracks the capital intensity of individual clinical trials and helps investors assess the progress and resource allocation for the company's lead oncolytic immunotherapy program.
Ask your AI about Replimune Group's business segments — rp1 program costs by study.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude